Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for fertility: drug may reverse early menopause in autoimmune patients

NCT ID NCT07509840

Recruiting now Disease control Sponsor: Angelica Lindén Hirschberg Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether an immunomodulatory drug (rituximab) can improve or normalize ovarian function in women aged 18-38 with autoimmune premature ovarian insufficiency (POI). Participants receive either rituximab or a placebo, and those who respond may undergo IVF. The goal is to restore fertility, but ongoing management may still be needed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOIMMUNE PREMATUR OVARIAN INSUFFIENCE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune primary ovarian failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AUTOIMMUNE PREMATUR OVARIAN INSUFFIENCE

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Department of Obstetrics and Gynecology, Karolinska University Hospital

    RECRUITING

    Stockholm, 171 76, Sweden

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Karolinska University Hospital

    RECRUITING

    Stockholm, 17176, Sweden

    Contact

    Contact Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••